Deal with Laboratoires Th éa representing a total value of up to $280 million including clinical, regulatory and commercial ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Belite Bio shares rose after the pharmaceutical company reported positive results in a Phase 3 trial of its Tinalrebant drug for eye disease. Shares were up 11% to $152.00 after hitting a 52-week high ...

While GlobalData analyst Sara Reci touted the DRAGON results as a “breakthrough” in STGD1, she noted that barriers to ...

The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced. This story first appeared in Healthy You - January 2025, The Gazette’s quarterly health publication.

HUC1-394 is a peptide-based eye drop for dry eyes, licensed from NOVACELL Technology. According to the company, HUC1-394 ...

When Vivian Kneller was an infant, her pediatrician told her parents that they needed to take her from their home in Knoxville, Tennessee, to an eye specialist in Nashville. That doctor told them to ...

The three-year initiative aims to develop two new treatments for glaucoma and myopia. Read more at straitstimes.com. Read ...

Four years ago, Carolyn Adelsten woke up feeling like something was in her eye and it wouldn’t come out. She visited an eye specialist, got a diagnosis of mild dry eye disease and was told to use ...

The Tear Film and Ocular Surface Society (TFOS) released the comprehensive TFOS Dry Eye Workshop II (DEWS II) guidelines in 2017, which served as a landmark update to the understanding and management ...

Deal with Laboratoires Théa representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility ...